William Whiteley
A5058224218- Acute Ischemic Stroke Management
- Cerebrovascular and Carotid Artery Diseases
- Stroke Rehabilitation and Recovery
- Blood Pressure and Hypertension Studies
- Intracerebral and Subarachnoid Hemorrhage Research
- Venous Thromboembolism Diagnosis and Management
- Dementia and Cognitive Impairment Research
- S100 Proteins and Annexins
- Health Systems, Economic Evaluations, Quality of Life
- Machine Learning in Healthcare
- Antiplatelet Therapy and Cardiovascular Diseases
- Topic Modeling
- Traumatic Brain Injury and Neurovascular Disturbances
- COVID-19 Clinical Research Studies
- Biomedical Text Mining and Ontologies
- Atrial Fibrillation Management and Outcomes
- Genetic Associations and Epidemiology
- Cardiovascular Health and Disease Prevention
- COVID-19 and healthcare impacts
- Neurosurgical Procedures and Complications
- Neurological Disorders and Treatments
- Intracranial Aneurysms: Treatment and Complications
- Atherosclerosis and Cardiovascular Diseases
- Chronic Disease Management Strategies
- Cardiac Imaging and Diagnostics
University of Edinburgh
2016-2025
University of Oxford
2015-2025
Population Health Research Institute
2023-2025
British Heart Foundation
2024-2025
Health Data Research UK
2020-2025
McMaster University
2024-2025
Medical Research Council
2022-2024
Cardiff University
2024
UK Dementia Research Institute
2022-2024
Hamilton Health Sciences
2024
Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide evidence-based recommendations to assist physicians in their clinical decisions regard intravenous were developed based on ESO standard operating procedure and followed Grading of Recommendations, Assessment, Development, Evaluation (GRADE) methodology. The working group identified relevant questions, performed...
Thrombolytic therapy with intravenous alteplase within 4.5 hours of ischemic stroke onset increases the overall likelihood an excellent outcome (no, or nondisabling, symptoms). Any improvement in functional distribution has value, and herein we provide assessment effect on level by treatment delay, age, severity.
Background: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a prothrombotic state, but long-term effects of COVID-19 on incidence vascular diseases are unclear. Methods: We studied after diagnosis in population-wide anonymized linked English and Welsh electronic health records from January 1 to December 7, 2020. estimated adjusted hazard ratios comparing the arterial thromboses venous thromboembolic events (VTEs) people without diagnosis. conducted...
Early control of elevated blood pressure is the most promising treatment for acute intracerebral haemorrhage. We aimed to establish whether implementing a goal-directed care bundle incorporating protocols early intensive lowering and management algorithms hyperglycaemia, pyrexia, abnormal anticoagulation, implemented in hospital setting, could improve outcomes patients with spontaneous
BackgroundAntiplatelet therapy reduces the risk of major vascular events for people with occlusive disease, although it might increase intracranial haemorrhage. Patients surviving commonest subtype haemorrhage, intracerebral are at both haemorrhagic and events, but whether antiplatelet can be used safely is unclear. We aimed to estimate relative absolute effects on recurrent haemorrhage this exceed any reduction events.MethodsThe REstart or STop Antithrombotics Randomised Trial (RESTART) was...
Abstract Objective To describe a novel England-wide electronic health record (EHR) resource enabling whole population research on covid-19 and cardiovascular disease while ensuring data security privacy maintaining public trust. Design Data comprising linked person level records from national healthcare settings for the English population, accessible within NHS Digital’s new trusted environment. Setting EHRs primary care, hospital episodes, death registry, laboratory test results, community...
The purpose of the European Stroke Organisation–Karolinska Update Conference is to provide updates on recent stroke therapy research and give an opportunity for participants discuss how these results may be implemented into clinical routine. meeting started 22 years ago as Karolinska Update, but since 2014 it a joint conference with Organisation. Importantly, provides platform discussion Organisation guidelines process recommendations committee specific topics. By this, adds direct influence...
Six randomized controlled clinical trials have assessed whether mechanical thrombectomy (MT) alone is non-inferior to intravenous thrombolysis (IVT) plus MT within 4.5 hours of symptom onset in patients with anterior circulation large vessel occlusion (LVO) ischemic stroke and no contraindication IVT. An expedited recommendation process was initiated by the European Stroke Organisation (ESO) conducted Society Minimally Invasive Neurological Therapy (ESMINT) according ESO standard operating...
Six randomized controlled clinical trials have assessed whether mechanical thrombectomy (MT) alone is non-inferior to intravenous thrombolysis (IVT) plus MT within 4.5 hours of symptom onset in patients with anterior circulation large vessel occlusion (LVO) ischaemic stroke and no contraindication IVT. An expedited recommendation process was initiated by the European Stroke Organisation (ESO) conducted Society Minimally Invasive Neurological Therapy (ESMINT) according ESO standard operating...
Thromboses in unusual locations after the Coronavirus Disease 2019 (COVID-19) vaccine ChAdOx1-S have been reported, although their frequency with vaccines of different types is uncertain at a population level. The aim this study was to estimate population-level risks hospitalised thrombocytopenia and major arterial venous thromboses COVID-19 vaccination.In whole-population cohort study, we analysed linked electronic health records from adults living England, 8 December 2020 18 March 2021. We...